Anavex Life Sciences Corp (AVXL)

[Investor2014]

Anavex, as any investor would know, have conducted a number clinical trials as required to potentially gain approval in humans.

So this lame attempt at rescuing your statement is just another fail.

So far, all of it is "preclinical," in the sense that the drug has not yet gained regulatory approval for sale or therapeutic uses in any humans.

Regarding below question:

Should the existing published research data on blarcamesine, in both animals and humans, guide us in any way about taking an AVXL position?

Of course it should, just not as a 'we got this' type proclaimed certainty of success in humans - just as said in my previous post.

Seems you are acting sensibly as in investor yourself. That same attribute should also be reflected as a 'trusted' scientific MB reference to others with less training in critically assessing biotech trials, data and company statements about same.